Methandrostenolone (Dianabol) for Rapid Mass & Strength — Anabolic Steroids
The first widely used oral anabolic steroid. Powerful mass builder with significant hepatotoxicity and estrogenic effects.
Overview
Methandrostenolone (Dianabol/Dbol) is historically the most iconic oral anabolic steroid, developed by Dr. John Ziegler in collaboration with CIBA in 1958 for the US Olympic team. It was the first widely available oral AAS and remains one of the most popular mass-building compounds. Dianabol is a modified form of testosterone with a 17-alpha-alkyl group (for oral bioavailability) and a 1,2 double bond (which reduces androgenic effects). It has a short half-life of 3-6 hours and strongly aromatizes to methylestradiol, causing significant water retention and potential gynecomastia. Despite being discontinued by CIBA and removed from most pharmaceutical markets, it remains widely manufactured. Known for producing rapid mass and strength gains (10-20 lbs in 4-6 weeks), much of which is water retention.
Indications
- No current FDA-approved indications (historically used for various wasting conditions)
- Rapid mass and strength accrual (non-medical)
- Strength plateaus and performance enhancement
- Cycle initiation ('kickstart') while waiting for longer esters to reach peak levels
- Historical medical use: osteoporosis, pituitary dwarfism (now replaced by better drugs)
Mechanism of Action
Desire for fast-onset muscle mass and strength gains, often as kickstart while waiting for injectable ester peak levels
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| Methandrostenolone (Dianabol) | 15-25 mg | Split 3-4 times daily | Conservative dosing for first-time use; split throughout day due to short half-life |
| Methandrostenolone (Dianabol) | 30-50 mg | Split 3-4 times daily | Standard dosing range; significant hepatotoxicity at higher end |
Evidence Grade
GRADE D
Safety & Contraindications
- 17-alpha-alkylated - SIGNIFICANT hepatotoxicity
- Schedule III controlled substance
- Strongly aromatizes to methylestradiol: significant water retention and gynecomastia risk
- Aromatase inhibitor (anastrozole/letrozole) often needed to control estrogen
- Severe HPTA suppression - PCT mandatory
- Dramatically worsens cholesterol profile
- Elevated blood pressure due to water retention and estrogenic effects
- Monitor liver function closely - limit cycle duration to 4-6 weeks
- Avoid alcohol and other hepatotoxic substances during use
- Can cause androgenic side effects: acne, hair loss, body hair
- Significant rapid weight gain is largely water - much is lost upon discontinuation